

What is IndiSwitch?

IndiSwitch is a Strategic Result Oriented Service from VLife. Under this engagement, VLife employs its proven VLifeRVHTS technology, VLifelRBS decision support system, NewEdge analysis platform and scientific expertise to discover putative off target binding of drug(s).

Why IndiSwitch is important to your business?

Line extension based new indication discovery is an established and well pursued strategy for product lifecycle management. However, change of paradigm from the product to the intrinsic active pharmaceutical ingredient (API) opens up an entirely new vista for maximizing the return on investment (RoI) on that API. The information on off-target binding of API can be viewed as an opportunity for development of molecule for new indication or can provide clues to possible side effects. Success in discovering new indications for an API can lead to either enhancing prescription space for an existing molecule by creating entirely new therapeutic product (making smart use of the safety & toxicity data already generated). The end result is significant improvement in RoI. An innovator company can expect to obtain patentable intellectual property (IP) for these new indications which can be commercially exploited in multiple ways. VLife provides full support to the customer to file respective patents for protecting IP so generated.

How does IndiSwitch engagement work?

When a client engages VLife for IndiSwitch for the API of their drug A, VLife computationally explores new putative targets for the API discovered through computational structural studies over about 1000+ therapeutically relevant targets in its database using proprietary VLifeRVHTS technology platform. The resulting output is sieved through VLifelRBS decision support system to filter out inconsequential computational output. The resulting data is manually analyzed by expert team of VLife's researchers using NewEdge analysis platform. As a result, VLife shortlists top-5 targets with which the API may interact sufficiently to impart a potential therapeutic effect.

This scope of IndiSwitch engagement can be extended at the option of the customer to include target binding study where the bio-assays are available, API – putative target binding study through crystallography, In-vivo studies etc. VLife delivers these extensions through its pre-qualified partners who are experts in their respective fields. Else, the customer may undertake these validation studies independently or seek VLife to manage these studies through their specified service providers.

